Imaging data from the CONTENTed study suggest the type 2 inflammation that drives severe asthma may affect more than the airways.
|Articles|March 1, 2022
Daily Medication Pearl: Canagliflozin (Invokana)
Author(s)Saro Arakelians, PharmD
Canagliflozin (Invokana) is indicated to improve glycemic control in adults with type 2 diabetes mellitus.
Advertisement
Medication Pearl of the Day: Canagliflozin (Invokana)
Indication: Canagliflozin (Invokana) is a sodium-glucose co-transporter 2 (SGLT2) inhibitor indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
Insight:
- Dosing: The recommended starting dose is 100 mg once daily, taken before the first meal of the day.
- Dosage forms: Tablets 100 mg, 300 mg.
- Adverse events: Most common adverse reactions associated with canagliflozin (5% or greater incidence): female genital mycotic infections, urinary tract infection, and increased urination.
- Mechanism of action: SGLT2 expressed in the proximal renal tubules is responsible for most of the reabsorption of filtered glucose from the tubular lumen. By inhibiting SGLT2, canagliflozin reduces reabsorption of filtered glucose and lowers the renal threshold for glucose, thereby increasing urinary glucose excretion.
- Manufacturer: Janssen Pharmaceuticals
Sources:
Advertisement
Related to this article
Renal benefit appeared only in patients with albuminuria in a 75,455-person BMJ analysis, while sulfonylureas signaled faster decline without it.
Authors of a pharmacist-directed transitions of care study discuss what drives pneumococcal vaccine hesitancy and how pharmacists can build systematic vaccine screening into inpatient workflows.
The investigational once-weekly dual GLP-1/GIP receptor agonist, engineered with signaling bias at both receptors, met both primary end points at 48 weeks.
HYPERION trial data now support sotatercept within a patient's first year of pulmonary arterial hypertension (PAH) diagnosis, cutting clinical worsening risk by 76% compared with placebo.
A stewardship program combining EHR alerts and pharmacist-led education offers a replicable model for reducing bleeding risk.
Tim Cernohous of Cencora explains why patient trust no longer guarantees satisfaction—and how automation and better communication can close the gap with mail order.
Eight Humira biosimilars have been launched, but payer formularies and interchangeability rules decide what dispenses.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Armored CAR T-Cell Therapy Produces Durable Complete Response in Pediatric Solid Tumors
2
Semaglutide Linked to Up to 40% Fewer Asthma Attacks, Real-World Data Show
3
Expert Q&A: Pharmacists Address Pneumococcal Vaccine Hesitancy and Screening Complexity in Transitions of Care
4
Not So Rare After All: Pharmacists Weigh In on Diagnosing and Managing ATTR-CM
5